List of Subsys drug patents
Subsys is owned by Btcp Pharma.
Subsys contains Fentanyl.
Subsys has a total of 10 drug patents out of which 0 drug patents have expired.
Subsys was authorised for market use on 04 January, 2012.
Subsys is available in spray;sublingual dosage forms.
Subsys can be used as treatment of pain.
The generics of Subsys are possible to be released after 27 April, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610523 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US8835460 | BTCP PHARMA | Sublingual fentanyl spray and methods of treating pain |
Jan, 2027
(3 years from now) | |
| US9642797 | BTCP PHARMA | Sublingual fentanyl spray and methods of use to treat pain |
Jan, 2027
(3 years from now) | |
| US9289387 | BTCP PHARMA | Method of treating pain by administering sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US9642844 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US8835459 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US10016403 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US9241935 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(3 years from now) | |
| US8486973 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(7 years from now) | |
| US8486972 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(7 years from now) | |
Drugs and Companies using FENTANYL ingredient
Market Authorisation Date: 04 January, 2012
Treatment: Treatment of pain
Dosage: SPRAY;SUBLINGUAL
SUBSYS family patents
17
United States
3
Japan
3
European Union
2
Portugal
2
Poland
2
Australia
2
Denmark
2
Mexico
2
Spain
2
Canada
1
Slovenia
1
New Zealand
1
Cyprus
1
Norway
1
Russia
1
China
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic